Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults

키워드

참고문헌 (174)

1. Solomkin JS, "Diagnosis and management of complicated intra-abdominal infection in adults and children : guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
2. Lopez N, "A Comprehensive review of abdominal infections", World J Emerg Surg, 6, pp.7~ (2011)
3. Sartelli M, "The management of intra-abdominal infections from a global perspective : 2017 WSES guidelines for management of intra-abdominal infections", World J Emerg Surg, 12, pp.29~ (2017)
4. Haddad N, "The 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial therapy in complicated intraabdominal infections in the era of antimicrobial resistance", BMC Infect Dis, 19, pp.293~ (2019)
5. Blot S, "Essentials for selecting antimicrobial therapy for intra-abdominal infections", Drugs, 72, pp.e17~32 (2012)
6. Mazuski JE, "The surgical infection society revised guidelines on the management of intra-abdominal infection", Surg Infect(Larchmt), 18, pp.1~76 (2017)
7. Gomi H, "Tokyo Guidelines 2018 : antimicrobial therapy for acute cholangitis and cholecystitis", J Hepatobiliary Pancreat Sci, 25, pp.3~16 (2018)
8. Montravers P, "Guidelines for management of intra-abdominal infections", Anaesth Crit Care Pain Med, 34, pp.117~130 (2015)
9. Chow AW, "Canadian practice guidelines for surgical intra-abdominal infections", Can J Infect Dis Med Microbiol, 21, pp.11~37 (2010)
10. Jandhyala SM, "Role of the normal gut microbiota", World J Gastroenterol, 21, pp.8787~8803 (2015)
11. Torer N, "Prognostic factors of the mortality of postoperative intraabdominal infections", Infection, 38, pp.255~260 (2010)
12. 대한감염학회, "소화기계 감염 진료지침 권고안", Infection and Chemotherapy, 42(6), pp.323~361 (2010), 대한감염학회
13. 윤영경, "Antimicrobial Susceptibility of Microorganisms Isolated from Patients with Intraabdominal Infection in Korea: a Multicenter Study", Journal of Korean Medical Science, 34(47), pp.1~13 (2019), 대한의학회
14. Yoon Young Kyung, "Guidelines on Implementing Antimicrobial Stewardship Programs in Korea", Infection and Chemotherapy, 53(3), pp.617~659 (2021), 대한감염학회[DOI]
15. Eckmann C, "Antimicrobial treatment of “complicated”intra-abdominal infections and the new IDSA guidelines? a commentary and an alternative European approach according to clinical definitions", Eur J Med Res, 16, pp.115~126 (2011)
16. Monneuse O, "Diagnosis and treatment of spontaneous group A streptococcal peritonitis", Br J Surg, 97, pp.104~108 (2010)
17. Rimola A, "Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis : a consensus document. International Ascites Club", J Hepatol, 32, pp.142~153 (2000)
18. Piano S, "Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide", Gastroenterology, 156, pp.1368~1380 (2019)
19. Fernández J, "Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis : a prospective study", Hepatology, 55, pp.1551~1561 (2012)
20. Sartelli M, "Complicated intra-abdominal infections worldwide : the definitive data of the CIAOW Study", World J Emerg Surg, 9, pp.37~ (2014)
21. De Waele J, "Abdominal infections in the intensive care unit : characteristics, treatment and determinants of outcome", BMC Infect Dis, 14, pp.420~ (2014)
22. Chow JW, "In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)", Surg Infect(Larchmt), 6, pp.439~448 (2005)
23. Yang Q, "Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China : the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends(SMART)", Int J Antimicrob Agents, 36, pp.507~512 (2010)
24. Chen YH, "Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria", J Infect, 62, pp.280~291 (2011)
25. Chen WT, "Improving diagnosis of central venous catheterrelated bloodstream infection by using differential time to positivity as a hospital-wide approach at a cancer hospital", J Infect, 59, pp.317~323 (2009)
26. Hsueh PR, "Study for Monitoring Antimicrobial Resistance Trends(SMART)in the Asia-Pacific region, 2002-2010", Int J Antimicrob Agents, 40(Suppl), pp.S1~S3 (2012)
27. Lee YL, "Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends(SMART)from 2006 to 2010", Int J Antimicrob Agents, 40(Suppl), pp.S29~S36 (2012)
28. Hawser SP, "In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007 : results from the SMART study", Int J Antimicrob Agents, 34, pp.585~588 (2009)
29. Kurup A, "Antibiotic management of complicated intra-abdominal infections in adults: The Asian perspective", Ann Med Surg(Lond), 3, pp.85~91 (2014)
30. Huang CC, "Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region : results from the Study for Monitoring Antimicrobial Resistance Trends(SMART), 2002-2010", Int J Antimicrob Agents, 40(Suppl), pp.S4~S10 (2012)
31. Syue LS, "New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance", Int J Antimicrob Agents, 47, pp.250~258 (2016)
32. Choi Hyeah, "Bloodstream Infections in Patients with Hematologic Diseases: Causative Organisms and Factors Associated with Resistance", Infection and Chemotherapy, 54(2), pp.340~352 (2022), 대한감염학회[DOI]
33. Choi Young Kyun, "Antibiotic Resistance Patterns of Enterobacteriaceae Isolated from Patients with Healthcare-Associated Infections", Infection and Chemotherapy, 53(2), pp.355~363 (2021), 대한감염학회[DOI]
34. Chang YT, "Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013", Int J Antimicrob Agents, 49, pp.734~739 (2017)
35. Marshall JC, "Intensive care unit management of intra-abdominal infection", Crit Care Med, 31, pp.2228~2237 (2003)
36. Schuetz AN, "Antimicrobial resistance and susceptibility testing of anaerobic bacteria", Clin Infect Dis, 59, pp.698~705 (2014)
37. 이양순, "Multicenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012", Annals of Laboratory Medicine, 35(5), pp.479~486 (2015), 대한진단검사의학회
38. 변정현, "Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species", Annals of Laboratory Medicine, 39(2), pp.190~199 (2019), 대한진단검사의학회[DOI]
39. Goldstein EJ, "Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy", J Antimicrob Chemother, 53(Suppl 2), pp.ii29~ii36 (2004)
40. Greer ND, "Tigecycline(Tygacil) : the first in the glycylcycline class of antibiotics", Proc Bayl Univ Med Cent, 19, pp.155~161 (2006)
41. Sitges-Serra A, "Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis", Br J Surg, 89, pp.361~367 (2002)
42. Burnett RJ, "Definition of the role of enterococcus in intraabdominal infection : analysis of a prospective randomized trial", Surgery, 118, pp.716~721 (1995)
43. Dupont H, "Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients", Arch Surg, 137, pp.1341~1346 (2002)
44. Biggins SW, "Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome : 2021 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 74, pp.1014~1048 (2021)
45. Goel A, "A real-world evaluation of repeat paracentesis-guided management of Spontaneous bacterial peritonitis", J Clin Gastroenterol, 51, pp.278~284 (2017)
46. Fiore M, "Are thirdgeneration cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 30, pp.329~336 (2018)
47. de Mattos AA, "Multi-resistant bacteria in spontaneous bacterial peritonitis : a new step in management?", World J Gastroenterol, 20, pp.14079~14086 (2014)
48. Piano S, "The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis : Results of a randomized, controlled clinical trial", Hepatology, 63, pp.1299~1309 (2016)
49. Sartelli M, "Management of intra-abdominal infections : recommendations by the WSES 2016 consensus conference", World J Emerg Surg, 12, pp.22~ (2017)
50. Kim SW, "Empirical treatment with carbapenem vs third-generation cephalosporin for treatment of Spontaneous Bacterial Peritonitis", Clin Gastroenterol Hepatol, 19, pp.976~986 (2021)
51. Evans L, "Surviving sepsis campaign : international guidelines for management of sepsis and septic shock 2021", Intensive Care Med, 47, pp.1181~1247 (2021)
52. Paul M, "Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis", Antimicrob Agents Chemother, 54, pp.4851~4863 (2010)
53. Hyeri Seok, "Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis", Infection and Chemotherapy, 52(1), pp.19~30 (2020), 대한감염학회[DOI]
54. Legendre DP, "Antibiotic hypersensitivity reactions and approaches to desensitization", Clin Infect Dis, 58, pp.1140~1148 (2014)
55. Sartelli M, "Antimicrobials : a global alliance for optimizing their rational use in intra-abdominal infections(AGORA)", World J Emerg Surg, 11, pp.33~ (2016)
56. Heizmann WR, "Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies", J Antimicrob Chemother, 68(Suppl 2), pp.ii45~ii55 (2013)
57. 주형욱, "지역사회획득 천공성 충수염의 세균학, 항생제 감수성, 경험적 항생 제에 대한 연구", Infection and Chemotherapy, 44(6), pp.439~445 (2012), 대한감염학회
58. Jeon HG, "Bacteriology and changes in antibiotic susceptibility in adults with community-acquired perforated appendicitis", PLoS One, 9, pp.e111144~ (2014)
59. Eckmann C, "Calculated parenteral initial treatment of bacterial infections : Intra-abdominal infections", GMS Infect Dis, 8, pp.Doc13~ (2020)
60. Montero A, "Antimicrobial management in nosocomial peritonitis : microbiota, drug and time", Rev Esp Quimioter, 30(Suppl 1), pp.34~38 (2017)
61. Dupont H, "Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis : a multicenter randomized controlled trial", Antimicrob Agents Chemother, 44, pp.2028~2033 (2000)
62. Tamma PD, "Combination therapy for treatment of infections with gramnegative bacteria", Clin Microbiol Rev, 25, pp.450~470 (2012)
63. Skrupky LP, "Current strategies for the treatment of complicated intraabdominal infections", Expert Opin Pharmacother, 14, pp.1933~1947 (2013)
64. Sung YK, "The clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial-resistant pathogens", Am J Gastroenterol, 107, pp.473~483 (2012)
65. Rerknimitr R, "Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis", Gastrointest Endosc, 56, pp.885~889 (2002)
66. Kang E, "Differences in bile microbiology and antibiotic resistances between liver transplant recipients and non-transplant patients", Surg Infect(Larchmt), 22, pp.741~751 (2021)
67. Kwon W, "Changing trend in bile microbiology and antibiotic susceptibilities : over 12 years of experience", Infection, 41, pp.93~102 (2013)
68. Karasawa Yuki, "Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium", Gut and Liver, 15(4), pp.616~624 (2021), 거트앤리버 소화기연관학회협의회[DOI]
69. Toh HS, "Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan : results from the Study for Monitoring Antimicrobial Resistance Trends(SMART), 2006-2010", Int J Antimicrob Agents, 40(Suppl), pp.S18~S23 (2012)
70. Reuken PA, "Risk factors for multi-drug resistant pathogens and failure of empiric first-line therapy in acute cholangitis", PLoS One, 12, pp.e0169900~ (2017)
71. 강철인, "Clinical and Molecular Epidemiology of Community-Onset Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli over a 6-Year Period", Journal of Korean Medical Science, 28(7), pp.998~1004 (2013), 대한의학회
72. 구자충, "Extended Spectrum-β-Lactamase or Carbapenemase Producing Bacteria Isolated from Patients with Acute Cholangitis", Clinical Endoscopy, 45(2), pp.155~160 (2012), 대한소화기내시경학회
73. Knitsch W, "A randomized, placebocontrolled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections", Clin Infect Dis, 61, pp.1671~1678 (2015)
74. Coccolini F, "Antibiotic resistance pattern and clinical outcomes in acute cholecystitis : 567 consecutive worldwide patients in a prospective cohort study", Int J Surg, 21, pp.32~37 (2015)
75. 권정석, "Changes in Causative Pathogens of Acute Cholangitis and Their Antimicrobial Susceptibility over a Period of 6 Years", 대한소화기학회지, 63(5), pp.299~307 (2014), 대한소화기학회
76. Jang DK, "Increasing burden of biliary tract infection caused by extended-spectrum beta-lactamase-producing organisms in Korea : A nationwide population-based study", J Gastroenterol Hepatol, 35, pp.56~64 (2020)
77. Jeon MH, "Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients", Diagn Microbiol Infect Dis, 62, pp.402~406 (2008)
78. 이효진, "Carbapenem-resistant Enterobacteriaceae: Prevalence and Risk Factors in a Single Community-Based Hospital in Korea", Infection and Chemotherapy, 48(3), pp.166~173 (2016), 대한감염학회
79. Ahn JY, "Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea : a matched case-control study", Am J Infect Control, 42, pp.621~625 (2014)
80. Park JW, "Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea", Antimicrob Resist Infect Control, 8, pp.48~ (2019)
81. Laterre PF, "Antimicrobial therapy for intra-abdominal infections : guidelines from the Infectious Disease Advisory Board(IDAB)", Acta Chir Belg, 106, pp.2~21 (2006)
82. Solomkin JS, "Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections", Clin Infect Dis, 37, pp.997~1005 (2003)
83. Nguyen MH, "Antimicrobial resistance and clinical outcome of Bacteroides bacteremia : findings of a multicenter prospective observational trial", Clin Infect Dis, 30, pp.870~876 (2000)
84. Snydman DR, "Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin : a retrospective analysis", Antimicrob Agents Chemother, 36, pp.540~544 (1992)
85. Gomi H, "Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis", J Hepatobiliary Pancreat Sci, 24, pp.310~318 (2017)
86. Rice LB, "Antimicrobial stewardship and antimicrobial resistance", Med Clin North Am, 102, pp.805~818 (2018)
87. Amábile-Cuevas Carlos F., "Myths and Misconceptions around Antibiotic Resistance: Time to Get Rid of Them", Infection and Chemotherapy, 54(3), pp.393~408 (2022), 대한감염학회[DOI]
88. Chen Q, "Risk factors for antibiotic resistance development in healthcare settings in China : a systematic review", Epidemiol Infect, 149, pp.e141~ (2021)
89. Pendleton JN, "Clinical relevance of the ESKAPE pathogens", Expert Rev Anti Infect Ther, 11, pp.297~308 (2013)
90. Rao GG, "Risk factors for the spread of antibiotic-resistant bacteria", Drugs, 55, pp.323~330 (1998)
91. Tacconelli E, "Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis", J Antimicrob Chemother, 61, pp.26~38 (2008)
92. Swenson BR, "Choosing antibiotics for intra-abdominal infections: what do we mean by “high risk”?", Surg Infect(Larchmt), 10, pp.29~39 (2009)
93. Wichai Santimaleeworagun, "Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections", Infection and Chemotherapy, 52(3), pp.345~351 (2020), 대한감염학회[DOI]
94. Wichai Santimaleeworagun, "Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection", Infection and Chemotherapy, 53(3), pp.503~511 (2021), 대한감염학회[DOI]
95. Núñez SA, "Antibiotic resistance in community-acquired intra-abdominal infections: Diabetes mellitus as a risk factor", Surg Infect(Larchmt), 21, pp.62~68 (2020)
96. Lodise TP, "Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections", BMC Infect Dis, 19, pp.718~ (2019)
97. El-Kholy A, "Landscape of multidrug-resistant gram-negative infections in Egypt : Survey and literature review", Infect Drug Resist, 14, pp.1905~1920 (2021)
98. Pfaller MA, "Activity of ceftolozanetazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens", Diagn Microbiol Infect Dis, 98, pp.115101~ (2020)
99. Timsit JF, "Rationalizing antimicrobial therapy in the ICU : a narrative review", Intensive Care Med, 45, pp.172~189 (2019)
100. Duong Bich Thuy, "Antibiotic-Resistant Gram-negative Bacteria Carriage in Healthcare Workers Working in an Intensive Care Unit", Infection and Chemotherapy, 53(3), pp.546~552 (2021), 대한감염학회[DOI]
101. Qureshi ZA, "Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases", Clin Microbiol Infect, 18, pp.887~893 (2012)
102. Tang SSL, "Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection : a prospective cohort study", Int J Antimicrob Agents, 57, pp.106340~ (2021)
103. Mora-Guzmán I, "Risk factors for intra-abdominal infections caused by carbapenemase-producing Enterobacteriaceae in a surgical setting", Surg Infect(Larchmt), 22, pp.864~870 (2021)
104. Wu D, "Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae", South Med J, 104, pp.106~110 (2011)
105. Seo Hyeonji, "Risk Factors for Mortality in Patients with Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae and Escherichia coli bacteremia", Infection and Chemotherapy, 53(3), pp.528~538 (2021), 대한감염학회[DOI]
106. Woerther PL, "Trends in human fecal carriage of extended-spectrum β-lactamases in the community : toward the globalization of CTX-M", Clin Microbiol Rev, 26, pp.744~758 (2013)
107. Wu CJ, "Clinical implications of species identification in monomicrobial Aeromonas bacteremia", PLoS One, 10, pp.e0117821~ (2015)
108. Rodríguez-Núñez O, "Antibiotic-resistant microorganisms in patients with bloodstream infection of intraabdominal origin : risk factors and impact on mortality", Infection, 49, pp.693~702 (2021)
109. Seguin P, "Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care", J Antimicrob Chemother, 65, pp.342~346 (2010)
110. Labricciosa FM, "Epidemiology and risk factors for isolation of multi-drug-resistant organisms in patients with complicated intra-abdominal infections", Surg Infect(Larchmt), 19, pp.264~272 (2018)
111. Zhang J, "Multi-drug-resistant bacterial infection after pancreatoduodenectomy: Risk factors and clinical impact", Surg Infect(Larchmt), 21, pp.793~798 (2020)
112. Li H, "Patients with cirrhosis and SBP : Increase in multidrug-resistant organisms and complications", Eur J Clin Invest, 50, pp.e13198~ (2020)
113. Rostkowska KA, "Spontaneous bacterial peritonitis-therapeutic challenges in the era of increasing drug resistance of bacteria", Clin Exp Hepatol, 4, pp.224~231 (2018)
114. Oey RC, "Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis : A study of two Dutch cohorts at a 10-year interval", United European Gastroenterol J, 6, pp.614~621 (2018)
115. Fernández J, "Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe", J Hepatol, 70, pp.398~411 (2019)
116. Barger M, "VRE in cirrhotic patients", BMC Infect Dis, 19, pp.711~ (2019)
117. Bartoletti M, "A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients", Clin Microbiol Infect, 24, pp.546~ (2018)
118. European Association for the Study of the Liver, "Electronic address : easloffice@easloffice. eu; European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
119. Fernández J, "Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage", Gastroenterology, 131, pp.1049~1056 (2006)
120. Marciano S, "Spontaneous bacterial peritonitis in patients with cirrhosis : incidence, outcomes, and treatment strategies", Hepat Med, 11, pp.13~22 (2019)
121. Dirchwolf M, "Unresolved issues in the prophylaxis of bacterial infections in patients with cirrhosis", World J Hepatol, 10, pp.892~897 (2018)
122. Acevedo J, "Multiresistant bacterial infections in liver cirrhosis : Clinical impact and new empirical antibiotic treatment policies", World J Hepatol, 7, pp.916~921 (2015)
123. Shizuma T, "Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis : A literature review", World J Hepatol, 10, pp.254~266 (2018)
124. Sofjan AK, "Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA", J Glob Antimicrob Resist, 15, pp.41~47 (2018)
125. Sunjaya DB, "Prevalence and predictors of thirdgeneration cephalosporin resistance in the empirical treatment of spontaneous bacterial peritonitis", Mayo Clin Proc, 94, pp.1499~1508 (2019)
126. Seguin P, "Factors associated with multidrug-resistant bacteria in secondary peritonitis : impact on antibiotic therapy", Clin Microbiol Infect, 12, pp.980~985 (2006)
127. Sokal A, "Acute cholangitis : Diagnosis and management", J Visc Surg, 156, pp.515~525 (2019)
128. Hu Y, "Developing a risk prediction model for multidrug-resistant bacterial infection in patients with biliary tract infection", Saudi J Gastroenterol, 26, pp.326~336 (2020)
129. Kawanishi K, "Appendectomy as a risk factor for bacteremic biliary tract infection caused by antibiotic-resistant pathogens", BioMed Res Int, 2017, pp.3276120~ (2017)
130. Suh SW, "Antibiotic selection based on microbiology and resistance profiles of bile from gallbladder of patients with acute cholecystitis", Sci Rep, 11, pp.2969~ (2021)
131. Yonkus JA, "Intraoperative bile duct cultures in patients undergoing pancreatic head resection : Prospective comparison of bile duct swab versus bile duct aspiration", Surgery, 170, pp.1794~1798 (2021)
132. Levy Hara G, "Ten key points for the appropriate use of antibiotics in hospitalised patients : a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy", Int J Antimicrob Agents, 48, pp.239~246 (2016)
133. Everts RJ, "Validity of cultures of fluid collected through drainage catheters versus those obtained by direct aspiration", J Clin Microbiol, 39, pp.66~68 (2001)
134. Haidar G, "Intra-abdominal infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice", Clin Transplant, 33, pp.e13595~ (2019)
135. Krobot K, "Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery", Eur J Clin Microbiol Infect Dis, 23, pp.682~687 (2004)
136. Hedrick TL, "Can we define the ideal duration of antibiotic therapy?", Surg Infect(Larchmt), 7, pp.419~432 (2006)
137. Bartlett JG, "Clinical recognition and diagnosis of Clostridium difficile infection", Clin Infect Dis, 46(Suppl 1), pp.S12~S18 (2008)
138. Fabian TC, "Duration of antibiotic therapy for penetrating abdominal trauma : a prospective trial", Surgery, 112, pp.788~794 (1992)
139. Bozorgzadeh A, "The duration of antibiotic administration in penetrating abdominal trauma", Am J Surg, 177, pp.125~131 (1999)
140. Kirton OC, "Perioperative antibiotic use in high-risk penetrating hollow viscus injury : a prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days", J Trauma, 49, pp.822~832 (2000)
141. Hjern F, "Conservative treatment of acute colonic diverticulitis : are antibiotics always mandatory?", Scand J Gastroenterol, 42, pp.41~47 (2007)
142. de Korte N, "Mild colonic diverticulitis can be treated without antibiotics. A case-control study", Colorectal Dis, 14, pp.325~330 (2012)
143. Chabok A, "Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis", Br J Surg, 99, pp.532~539 (2012)
144. Shabanzadeh DM, "Antibiotics for uncomplicated diverticulitis", Cochrane Database Syst Rev, 11, pp.CD009092~ (2012)
145. Desai M, "Antibiotics versus no antibiotics for acute uncomplicated diverticulitis : A systematic review and meta-analysis", Dis Colon Rectum, 62, pp.1005~1012 (2019)
146. Mui LM, "Optimum duration of prophylactic antibiotics in acute non-perforated appendicitis", ANZ J Surg, 75, pp.425~428 (2005)
147. Regimbeau JM, "Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis : a randomized clinical trial", JAMA, 312, pp.145~154 (2014)
148. Basoli A, "A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection", J Gastrointest Surg, 12, pp.592~600 (2008)
149. Sawyer RG, "Trial of short-course antimicrobial therapy for intraabdominal infection", N Engl J Med, 372, pp.1996~2005 (2015)
150. Lennard ES, "Leukocytosis at termination of antibiotic therapy : its importance for intra-abdominal sepsis", Arch Surg, 115, pp.918~921 (1980)
151. Lennard ES, "Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis", Ann Surg, 195, pp.19~24 (1982)
152. Daneman N, "Antibiotic treatment duration for bloodstream infections in critically ill patients : a national survey of Canadian infectious diseases and critical care specialists", Int J Antimicrob Agents, 38, pp.480~485 (2011)
153. Visser MR, "Predictors of recurrence of fulminant bacterial peritonitis after discontinuation of antibiotics in open management of the abdomen", Eur J Surg, 164, pp.825~829 (1998)
154. Havey TC, "Duration of antibiotic therapy for critically ill patients with bloodstream infections : A retrospective cohort study", Can J Infect Dis Med Microbiol, 24, pp.129~137 (2013)
155. Havey TC, "Duration of antibiotic therapy for bacteremia : a systematic review and meta-analysis", Crit Care, 15, pp.R267~ (2011)
156. Riccio LM, "Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections", Surg Infect(Larchmt), 15, pp.417~424 (2014)
157. Samuelsson A, "Changes in the aerobic faecal flora of patients treated with antibiotics for acute intra-abdominal infection", Scand J Infect Dis, 44, pp.820~827 (2012)
158. Montravers P, "Short-course antibiotic therapy for critically ill patients treated for postoperative intraabdominal infection : the DURAPOP randomised clinical trial", Intensive Care Med, 44, pp.300~310 (2018)
159. Bassetti M, "A research agenda on the management of intra-abdominal candidiasis : results from a consensus of multinational experts", Intensive Care Med, 39, pp.2092~2106 (2013)
160. Montravers P, "Candida as a risk factor for mortality in peritonitis", Crit Care Med, 34, pp.646~652 (2006)
161. Dupont H, "Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?", Crit Care Med, 31, pp.752~757 (2003)
162. Montravers P, "Intra-abdominal candidiasis : the guidelines-forgotten noncandidemic invasive candidiasis", Intensive Care Med, 39, pp.2226~2230 (2013)
163. León C, "What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients", Intensive Care Med, 40, pp.808~819 (2014)
164. Riché FC, "Factors associated with septic shock and mortality in generalized peritonitis : comparison between community-acquired and postoperative peritonitis", Crit Care, 13, pp.R99~ (2009)
165. Hasibeder W, "Candida peritonitis", Minerva Anestesiol, 80, pp.470~481 (2014)
166. Yoon YK, "Clinical implications of multidrugresistant microorganisms and fungi isolated from patients with intra-abdominal infections in the Republic of Korea : a multicenter study", Diagn Microbiol Infect Dis, 100, pp.114960~ (2021)
167. Pemán J, "Jávea consensus guidelines for the treatment of Candida peritonitis and other intra-abdominal fungal infections in non-neutropenic critically ill adult patients", Rev Iberoam Micol, 34, pp.130~142 (2017)
168. Li WS, "Antifungal therapy did not improve outcomes including 30-day all-cause mortality in patients suffering community-acquired perforated peptic ulcer-associated peritonitis with Candida species isolated from their peritoneal fluid", J Microbiol Immunol Infect, 50, pp.370~376 (2017)
169. Montravers P, "Antifungal therapy for patients with proven or suspected Candida peritonitis : Amarcand2, a prospective cohort study in French intensive care units", Clin Microbiol Infect, 23, pp.117~ (2017)
170. Eggimann P, "Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients", Crit Care Med, 27, pp.1066~1072 (1999)
171. Pramod J, "Clinical significance of Candida in an intraoperative peritoneal specimen with perforation peritonitis : An institutional perspective", Cureus, 10, pp.e2275~ (2018)
172. Montravers P, "Unmet needs in the management of intra-abdominal infections", Expert Rev Anti Infect Ther, 15, pp.839~850 (2017)
173. Bassetti M, "Role of antifungal therapy in complicated intraabdominal infections", Curr Infect Dis Rep, 22, pp.1~8 (2020)
174. Won EJ, "Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea : application of new antifungal breakpoints and relationship to antifungal usage", PLoS One, 10, pp.e0118770~ (2015)

관련 논문AI추천